**Core Concept**
Idiopathic central precocious puberty (ICPP) is a condition characterized by the early onset of pubertal changes, typically before the age of 8 in girls and 9 in boys, without any identifiable cause. The treatment aims to delay or halt the progression of puberty until a more appropriate age.

**Why the Correct Answer is Right**
The medication used to treat ICPP is a Gonadotropin-Releasing Hormone (GnRH) agonist. GnRH agonists work by initially stimulating the pituitary gland to release gonadotropins (LH and FSH), which then leads to a surge in sex hormone production. However, with prolonged use, the GnRH agonists downregulate the GnRH receptors in the pituitary gland, resulting in a decrease in LH and FSH secretion, and subsequently, a decrease in sex hormone production. This effect temporarily halts the progression of puberty.

**Why Each Wrong Option is Incorrect**
**Option A:** This option is incorrect because antihormones such as tamoxifen are not used to treat ICPP. Tamoxifen is an estrogen receptor antagonist used primarily in the treatment and prevention of breast cancer.
**Option B:** This option is incorrect because selective estrogen receptor modulators (SERMs) like raloxifene are used for osteoporosis and breast cancer prevention, not for treating ICPP.
**Option C:** This option is incorrect because aromatase inhibitors are used to treat conditions like gynecomastia and polycystic ovary syndrome (PCOS) by reducing estrogen levels, not to treat ICPP.

**Clinical Pearl / High-Yield Fact**
GnRH agonists can be used to treat ICPP, but it's essential to note that they must be administered via subcutaneous or intramuscular injection every 1-4 weeks, depending on the formulation.

**Correct Answer:** C.